psychedelic investment


Microdosing: The Next Revolution in Psychedelics

April 22nd, 2021 - Ryan Allway

The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders. As states liberalize their psychedelics regulations, microdosing […]

Psychedelics Wellness Company Delic: Proven Management Team with a Star-Studded Board

April 9th, 2021 - Ryan Allway

The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s […]

Es gibt keine magische Antwort auf die Frage “Kann ich Zauberpilze patentieren lassen?”

February 26th, 2021 - Ryan Allway

“Patent angemeldet” ist ein Ausdruck, mit dem Sie wahrscheinlich vertraut sind. Sie haben gesehen, wie es auf der Seite eines Dinges im Einkaufszentrum gestempelt wurde, oder Sie haben es in der Fernsehsendung gehört, die Sie gerade anschauen, und Sie denken sich: „Wow, ich wünschte, ich könnte etwas erfinden, das jeder für wirklich cool hält.“ Die […]

There’s no Magic Answer to the Question, “Can I Patent Magic Mushrooms?”

February 24th, 2021 - Ryan Allway

“Patent pending” is a phrase you are likely familiar with. You have seen it stamped on the side of some doodad at the mall or heard it on the TV show that you are binge watching, and you think to yourself, “Wow, I wish I could invent something that everyone thinks is really cool”. Most […]

Silo Pharma: A Capital Efficient Strategy Targeting Psychedelics

February 23rd, 2021 - Ryan Allway

Psychedelics have the potential to revolutionize mental health disorders that have been woefully underserved by conventional therapies. According to Data Bridge Market Research, psychedelic drug sales will grow from just over $2 billion in 2019 to over $6.8 billion by 2027, which represents a 16.3% compound annual growth rate. Investors have many different options for […]

Psychedelics: Significant Investor Interest Despite the Pandemic

February 16th, 2021 - Ryan Allway

  The COVID-19 pandemic may be ravaging large swaths of the economy, but the stock market has consistently hit new record highs. After spending several years under-the-radar, the psychedelics industry is experiencing a renaissance driven by a combination of FDA-driven catalysts and soaring investor interest in a new class of potential blockbuster therapeutics.  Let’s take […]

Combining Traditional Therapies with Psychedelics: SiloPharma Targeting CNS and Neurological Disorders

February 4th, 2021 - Ryan Allway

“Psychedelics” is a buzz word on Wall Street, but much like legal cannabis or bitcoin and blockchain a decade ago, it remains greatly misunderstood as the market emerges. There was a time when psychedelics were only perceived as part of the illicit drug culture. That stigma is disappearing. Loaded with promise, the burgeoning market includes […]

Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund

January 22nd, 2021 - Ryan Allway

VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund (“ETF”). The ETF will begin […]

MagicMed: Bringing the Drug Candidate Library Model to Psychedelics

January 20th, 2021 - Ash Stringer

The psychedelics market is often described as “emerging”, “burgeoning”, and other similar words, and while certainly true to a large extent, investors shouldn’t think for a moment this is all new. It’s far from it. There are scores of clinical and preclinical data to leverage, most collected before the Controlled Substance Act was enacted in […]

MagicMed Shortcuts Commercialization Timeline with University Agreement

November 4th, 2020 - Ryan Allway

Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations for certain therapies targeting life-threatening conditions. MagicMed Industries Inc., a developer of licensable psychedelic molecular derivatives, […]

Wie groß ist die psychedelische Gelegenheit?

October 29th, 2020 - Ryan Allway

Der nordamerikanische Markt für psychedelische Medikamente wird vorraussichtlich bis 2027 6.85 Milliarden USD erreichen, nach Daten der Data Bride Market Research, das entspricht einer jährlichen Wachstumsrate von 16.3%. Nach der Genehmigung von Johnson & Johnsons (NYSE: jnj) SPRAVATO Nasenspray für behandlusngsresistente Depressionen und zwei Breakthrough Therapie Bezeichnungen, sind Unternehmen, die Kapital beschaffen, um die  Multi-Milliarden-Dollar […]

3 Psychedelic Business Models (and What’s Best for Investors)

October 22nd, 2020 - Ryan Allway

The psychedelics industry has captured the interest of pharmaceutical companies seeking safer and more effective products to address unmet medical needs in mental health. While psychedelic molecules have shown promise, pharmaceutical manufacturers are likely to require that the molecules be improved through scientific engineering to meet specific therapeutic goals and reduce toxicities. There are three […]

Why Psychedelic Delivery Mechanisms Matter

October 2nd, 2020 - Ryan Allway

  The psychedelics industry is poised to become a nearly $7 billion market by 2027, according to Data Bridge Market Research, driven by the potential to revolutionize the treatment of mental health disorders. While investors have many options in the space, the best positioned companies are combining delivery mechanisms with novel compounds to create IP […]

Pure Extracts: A Proven Extraction Company with Laser Focus

September 22nd, 2020 - Ryan Allway

  Investors familiar with the cannabis and psychedelics industry know that most publicly traded companies are reverse mergers orchestrated by financiers. With strong investor interest, these financiers focused on raising as much capital as possible before starting to build a tangible business – many didn’t even have experience in the cannabis or psychedelics space! Of […]

Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer

April 6th, 2020 - Ryan Allway

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading